Characterization of a new class of androgen receptor antagonists with potential therapeutic application in advanced prostate cancer

Molecular Cancer Therapeutics

Volumn 12, Issue 11, 2013, Pages 2425-2435

  Li, Huifang ^a   Hassona, Mohamed D H ^a,e   Lack, Nathan A ^a,b   Axerio Cilies, Peter ^a   Leblanc, Eric ^a   Tavassoli, Peyman ^a   Kanaan, Natalia ^a   Frewin, Kate ^a   Singh, Kriti ^a   Adomat, Hans ^a   Böhm, Konrad J ^c   Prinz, Helge ^d   Guns, Emma Tomlinson ^a   Rennie, Paul S ^a   Cherkasov, Artem ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b KOÇ UNIVERSITY   (Turkey)

^c FRITZ LIPMANN INSTITUTE   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e Ein Helwan   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

10 BENZYLIDENE 10H ANTHRACEN 9 ONE; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; BENZYLIDENE DERIVATIVE; ENZALUTAMIDE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; VPC 3033;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN LNCAP; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION;

ANDROGEN RECEPTOR ANTAGONISTS; ANIMALS; ANTHRACENES; BENZYLIDENE COMPOUNDS; BINDING SITES; CELL LINE, TUMOR; DATABASES, FACTUAL; DISEASE MODELS, ANIMAL; HELA CELLS; HUMANS; MALE; MICE, NUDE; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887454928     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Fleshner N. Defining high-risk prostate cancer: current status. Can J Urol 2005;12 Suppl 1:14-7; discussion 94-6.
2. Kent EC, Hussain MHA. The patient with hormone-refractory prostate cancer: determining who, when, and how to treat. Urology 2003;62:134-40.
3. Martel CL, Gumerlock PH, Meyers FJ, Lara PN. Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev 2003;29:171-87.
4. Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, et al. Androgen receptor mutations in androgen-independent prostate cancer: cancer and Leukemia Group B Study 9663. J Clin Oncol 2003;21:2673-8.
5. Tilley WD, Lim-Tio SS, Horsfall DJ, Aspinall JO, Marshall VR, Skinner JM. Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis. Cancer Res 1994;54:4096-102.
6. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 1995;55:3068-72.
7. Rennie PS, Nelson CC. Epigenetic mechanisms for progression of prostate cancer. Cancer Metastasis Rev 1998;17:401-9.
8. Bohl CE, Wu ZR, Miller DD, Bell CE, Dalton JT. Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design. J Biol Chem 2007;282:13648-55.
9. Bohl CE, Gao WQ, Miller DD, Bell CE, Dalton JT. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci U S A 2005;102:6201-6.
10. Bohl CE, Miller DD, Chen JY, Bell CE, Dalton JT. Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. J Biol Chem 2005;280:37747-54.
11. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787-90.
12. Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, et al. ARN- 509: a novel antiandrogen for prostate cancer treatment. Cancer Res 2012;72:1494-503.
13. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 2012; 72:483-9.
14. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004;47: 1739-49.
15. Zsoldos Z, Reid D, Simon A, Sadjad SB, Johnson AP. eHiTS: a new fast, exhaustive flexible ligand docking system. J Mol Graph Model 2007;26:198-212.
16. Irwin JJ, Shoichet BK. ZINC-a free database of commercially available compounds for virtual screening. J Chem Inf Model 2005;45:177-82.
17. Cantin L, Faucher F, Couture JF, de Jesus-Tran KP, Legrand P, Ciobanu LC, et al. Structural characterization of the human androgen receptor ligand-binding domain complexed with EM5744, a rationally designed steroidal ligand bearing a bulky chain directed toward helix 12. J Biol Chem 2007;282:30910-9.
18. Zhou XE, Suino-Powell KM, Li J, He YZ, MacKeigan JP, Melcher K, et al. Identification of SRC3/AIB1 as a preferred coactivator for hormone-activated androgen receptor. J Biol Chem 2010;285: 9161-71.
19. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The protein data bank. Nucleic Acids Res 2000;28:235-42.
20. Suite 2011: Glide, version 5.7. New York, NY: Schrödinger, LLC; 2011.
21. Prinz H, Ishii Y, Hirano T, Stoiber T,Gomez JAC, Schmidt P, et al. Novel benzylidene-9(10H)-anthracenones as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization. J Med Chem 2003;46:3382-94.
22. Tavassoli P, Snoek R, Ray M, Rao LG, Rennie PS. Rapid, nondestructive, cell-based screening assays for agents that modulate growth, death, and androgen receptor activation in prostate cancer cells. Prostate 2007;67:416-26.
23. Kuruma H, Matsumoto H, Shiota M, Bishop JL, Lamoureux F, Thomas C, et al. A novel anti-androgen, Compound 30, suppresses castrationresistant and MDV3100-resistant prostate cancer growth in vitro and in vivo. Mol Cancer Ther 2013;12:567-76.
24. Axerio-Cilies P, Lack NA, Nayana MRS, Chan KH, Yeung A, Leblanc E, et al. Inhibitors of androgen receptor activation function-2 (AF2) site identified through virtual screening. J Med Chem 2011;54: 6197-205.
25. Lack NA, Axerio-Cilies P, Tavassoli P, Han FQ, Chan KH, Feau C, et al. Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening. J Med Chem 2011;56:1136-48.
26. Cheng H, Snoek R, Ghaidi F, Cox ME, Rennie PS. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Res 2006; 66:10613-20.
27. Prinz H, Chamasmani B, Vogel K, Bohm KJ, Aicher B, Gerlach M, et al. N-benzoylated phenoxazines and phenothiazines: synthesis, antiproliferative activity, and inhibition of tubulin polymerization. J Med Chem 2011;54:4247-63.
28. Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, et al. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 1999; 5:2891-8.
29. De Jesus-Tran KP, Cote PL, Cantin L, Blanchet J, Labrie F, Breton R. Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity. Protein Sci 2006;15:987-99.
30. He B, Gampe RT, Kole AJ, Hnat AT, Stanley TB, An G, et al. Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol Cell 2004;16:425-38.
31. Bohl CE, Wu ZR, Chen JY, Mohler ML, Yang J, Hwang DJ, et al. Effect of B-ring substitution pattern on binding mode of propionamide selective androgen receptor modulators. Bioorg Med Chem Lett 2008;18:5567-70.
32. Zsoldos Z, Reid D, Simon A, Sadjad BS, Johnson AP. eHITS: an innovative approach to the docking and scoring function problems. Curr Protein Pept Sci 2006;7:421-35.
33. Molecular Operating Environment (MOE), version 2010. Montreal, Quebec, Canada: Chemical Computing Group, Inc.; 2010.
34. Wang RX, Lai LH, Wang SM. Further development and validation of empirical scoring functions for structure-based binding affinity prediction. J Comput Aid Mol Des 2002;16:11-26.
35. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003;21:383-91.
36. Elshafie SMM. Synthesis of 10-arylidene-9-anthrones and related compounds. Indian J Chem B 1978;16:828-30.
37. Sato N, Gleave ME, Bruchovsky N, Rennie PS, Beraldi E, Sullivan LD. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice. CancerRes 1997;57:1584-9.
38. Muller K, Gurster D, Piwek S, Wiegrebe W. Antipsoriatic anthrones with modulated redox properties. 1. Novel 10-substituted 1,8-dihydroxy-9 (10h)-anthracenones as inhibitors of 5-lipoxygenase. J Med Chem 1993;36:4099-107.
39. Zhang LS, Lau YK, Xi L, Hong RL, Kim DS, Chen CF, et al. Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neuinduced cellular transformation and metastasis-associated properties. Oncogene 1998;16:2855-63.
40. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003;63:149-53.